1 by synchronization to environmental cues and is involved in diverse physiological processes 2 such as the regulation of blood pressure and core body temperature, oncogenesis, and immune function 3 . Melatonin is formed in the pineal gland in a light-regulated manner 4 by enzymatic conversion from 5-hydroxytryptamine (5-HT or serotonin), and modulates sleep and wakefulness 5 by activating two high-affinity G-proteincoupled receptors, type 1A (MT 1 ) and type 1B (MT 2 ) 3,6 . Shift work, travel, and ubiquitous artificial lighting can disrupt natural circadian rhythms; as a result, sleep disorders affect a substantial population in modern society and pose a considerable economic burden 7 . Over-the-counter melatonin is widely used to alleviate jet lag and as a safer alternative to benzodiazepines and other sleeping aids 8, 9 , and is one of the most popular supplements in the United States
. Here, we present high-resolution room-temperature X-ray free electron laser (XFEL) structures of MT 1 in complex with four agonists: the insomnia drug ramelteon 11 , two melatonin analogues, and the mixed melatonin-serotonin antidepressant agomelatine 12, 13 . The structure of MT 2 is described in an accompanying paper 14 . Although the MT 1 and 5-HT receptors have similar endogenous ligands, and agomelatine acts on both receptors, the receptors differ markedly in the structure and composition of their ligand pockets; in MT 1 , access to the ligand pocket is tightly sealed from solvent by extracellular loop 2, leaving only a narrow channel between transmembrane helices IV and V that connects it to the lipid bilayer. The binding site is extremely compact, and ligands interact with MT 1 mainly by strong aromatic stacking with Phe179 and auxiliary hydrogen bonds with Asn162 and Gln181. Our structures provide an unexpected example of atypical ligand entry for a non-lipid receptor, lay the molecular foundation of ligand recognition by melatonin receptors, and will facilitate the design of future tool compounds and therapeutic agents, while their comparison to 5-HT receptors yields insights into the evolution and polypharmacology of G-protein-coupled receptors.
To investigate the basis of ligand recognition by MT 1 , we crystallized the receptor using an intracellular loop 3 fusion with Pyrococcus abyssi glycogen synthase (PGS) 15 . To increase receptor thermostability, we introduced nine point mutations (D73 16 , see Methods), which were essential for crystallization. In combination, these modifications result in an approximately 40-fold reduction in melatonin affinity (approximately 14-fold in the presence of a physiological concentration of sodium; Extended Data Table 1) , primarily caused by the allosteric sodium site 17 mutation D73 2.50 N, which is known to affect coupling to G proteins 18 , and N299 8. 47 D, which is located at the G protein interface (Extended Data Tables 1 and 2) .
MT 1 was crystallized in lipidic cubic phase (LCP; Extended Data Fig. 1 ), and serial femtosecond crystallography (SFX) was used to obtain structures of MT 1 bound to the insomnia drug ramelteon (2.8 Å resolution), the high-affinity agonist 2-phenylmelatonin (2-PMT; 2.9 Å), 2-iodomelatonin, and agomelatine (both 3.2 Å). Data collection and refinement statistics for all MT 1 structures are provided in Extended Data Table 3 . The overall receptor conformation in all four structures is nearly identical (Cα root mean squared deviation (r.m.s.d.) < 0.3 Å); therefore, we focus our analysis below on the highest-resolution MT 1 -ramelteon structure unless otherwise noted.
The structure of MT 1 displays the canonical GPCR topology of a heptahelical transmembrane bundle (7TM) with an extracellular N terminus, three extracellular loops (ECLs), three intracellular loops (ICLs), and a short amphipathic helix VIII oriented parallel to the membrane (Fig. 1) . On the basis of structural alignment with the active 19 and inactive states 20 of the β 2 -adrenoreceptor (β 2 AR), we concluded that the 7TM of MT 1 is captured in an inactive conformation. Similar inactive states have been observed for agonist-bound complexes without intracellular binding partners of some GPCRs that have naturally weak coupling between the extracellular and intracellular sides (for example, β 2 AR), or those in which this coupling was disrupted by mutations 21, 22 . ECL2 forms a short β-hairpin anchored to helix III by the conserved disulfide bridge between C100 3. 25 and C177 ECL2 and a number of polar interactions with helices III, VI and VII, tightly sealing off the extracellular entrance to the orthosteric binding site (Fig. 1) , which is among the smallest of any receptor solved to date (710 Å 3 ; Extended Data Table 4 ). Potential ligand access to the orthosteric binding site is provided by a channel between helices IV and V that opens towards the lipid bilayer (Fig. 1b, d ). The channel is located about 7-11 Å below the hydrophobic membrane boundary, is about 10 Å long from the entrance to the centre of the ligand binding site, has a minimum diameter of 3 Å (about 4-5 Å otherwise), and is lined with a number of hydrophobic residues and H195 5.46 , which is highly conserved in melatonin receptors.
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A part of helix II that participates in shaping the ligand binding pocket contains a distinct YPYP motif (residues Y79 2.56 to P82 2. 59 ), which introduces a bulge and kink to helix II and places the ring planes of its tyrosine residues in an antiparallel orientation (Fig. 1c) . This YPYP motif is unique to melatonin receptors and the closely related orphan receptor GPR50. It is not found in any other membrane protein structures or predicted transmembrane segments of the human proteome (see Methods). Although P82 2.59 is conserved across class A receptors (74% of receptors), an equivalent of P80 2.57 is not present in any other human GPCR 22 . Mutation of any residue in the YPYP motif lowers thermostability by 6-10 °C and impairs receptor function (Extended Data Tables 5, 6 ), suggesting that this motif is an important structural element of melatonin receptors that contributes to receptor stability and activation.
Melatonergic ligands display a remarkably limited number of chemotypes. Indeed, over 80% of high-affinity melatonin ligands (from 391 compounds in ChEMBL24 23 (https://www.ebi.ac.uk/chembl/) with MT 1 affinity of less than 100 nM), most of which are agonists, possess a core that is either a (hetero)indene (mostly indole, benzofuran, benzoxazole) or a naphthalene bioisostere. We crystallized MT 1 with ligands from both of these major chemotypes, and together they revealed the conserved receptor interaction points and pharmacophore of melatonergic ligands.
Ramelteon engages in three anchoring interactions, including aromatic stacking of its heterocyclic core with F179
ECL2
, and hydrogen bonds between its alkylamide tail and Q181
ECL2 and between its dihydrofuran moiety and N162 4.60 (Fig. 2a) . The methoxy and alkylamide groups of 2-PMT, 2-iodomelatonin, and agomelatine (Fig. 2b ) interact with N162
4.60 and Q181 ECL2 in a similar manner to ramelteon.
The ligand core forms a close contact with G108
3. 33 , suggesting that a larger residue in this position would clash with the ligand. Indeed, the G108 3. 33 A mutation practically abolishes ligand binding (Extended Data Table 5 ). The binding site contains a hydrophobic sub-pocket, which accommodates the phenyl and iodine substituents of the cocrystallized melatonin analogues (Fig. 2c) .
Mutations of the ligand coordinating residues F179 ECL2 A and Q181 ECL2 A are detrimental to receptor stability and activation (Extended Data Tables 5, 6), while Q181 ECL2 E is functionally better tolerated. The N162 4.60 A mutation inactivates the receptor (Extended Data Table 6 ) but does not affect ligand affinity or receptor stability (Extended Data Tables 1, 5 ), reflecting the importance of the methoxy or equivalent substituent for ligand efficacy 24 . These findings are consistent with molecular dynamics simulations of the receptor-ligand complexes (Extended Data Fig. 2 ), wherein equilibrium interactions between ligands and two anchor residues, F179 ECL2 and Q181 ECL2 , are very stable and are stronger than the interaction with N162 4.60 . Together, these findings explain the tight steric fit and lipophilic interactions between ligands and receptor, mainly mediated by ECL2, as primary determinants of affinity. The importance of ECL2 for ligand binding in melatonin receptors is further highlighted by the recent demonstration that transplanting ECL2 of MT 1 to GPR50, a paralogue melatonin-related receptor that does not bind melatonin 25 , is sufficient to restore ligand-dependent activation in the resulting chimaera 26 . Analysis of the otherwise remarkably conserved binding site shows that the main difference between MT 1 or MT 2 and GPR50 is in ECL2 (Fig. 2d) .
Notably, although residue N255 6.52 does not interact with ligands in our structures (Fig. 2a, c) , and mutation N255 Letter reSeArCH residue might be involved in receptor activation. Small ligands such as melatonin or agomelatine are affected more strongly by these effects than bulkier ligands (Extended Data Fig. 2e , Extended Data Table 6 ). In all of our MT 1 structures we observe a small blob of electron density (about 6σ in mF o − DF c maps) close to N255 6.52 (Extended Data  Fig. 1e ) . We tentatively attribute this density to propan-2-ol, an essential additive in the crystallization of MT 1 . This additive was not needed to crystallize MT 2 , in which mutation of N 6.52 does not affect signalling 14 . Under physiological conditions, N255 6.52 is likely to remain hydrated rather than interacting directly with the ligand, as also suggested by our molecular dynamics simulations (Extended Data Fig. 2d ).
The existence of the lateral channel is supported by studies of the bitopic ligand CTL 01-05-B-A05, a symmetrical agomelatine dimer linked by an ethoxyethane spacer (see Methods). This ligand was docked into the MT 1 binding site, indicating that it can be accommodated only if its aliphatic linker region protrudes through the channel, and, therefore, one of its monomers must pass through the channel upon binding (Fig. 3) . We chose a residue in the vicinity of the channel entrance and designed a point mutation (A190 5.41 F) that was predicted to keep the channel open but would interfere with the placement of peripheral moieties of the bitopic ligand. Signalling for monotopic ligands was only slightly affected, whereas the bitopic ligand lost about one order of magnitude in potency (Extended Data Table 7 ). On the other hand, mutation A158 4. 56 M, which was designed to block the channel, caused loss of functional activity for all tested agonists, consistent with the hypothesis that the ligand entry in MT 1 is largely defined by the lateral channel.
Melatonin and serotonin are ancient molecules with physiological roles that predate the evolution of nervous systems, multicellularity and their appropriation as a hormone and a neurotransmitter, Letter reSeArCH respectively 27, 28 . Their primordial functions, which result from their chemical properties, are still evident by their occurrence in plants and their antioxidant abilities 27, 28 . The structural similarity and overlapping biosynthetic pathways of melatonin and serotonin contrast with their very different pharmacological roles and physicochemical parameters. Melatonin is soluble in both water and lipids and can traverse membranes by passive diffusion, whereas serotonin, owing to its charge, has to be secreted and actively transported 29 . Strikingly, 98% of high-affinity melatonin receptor ligands (<100 nM in the ChEMBL database) are neutral at physiological pH, whereas, depending on subtype, 80-99% of 5-HT receptor ligands are charged (see Methods).
Melatonin and 5-HT receptors share a low level of sequence identity (about 20-25%) and even lower binding site identity (1 out of 16 residues; Fig. 4d ). A key question is how these receptor families evolved to bind structurally similar endogenous molecules while maintaining orthogonal functions. Very few ligands bind both melatonin and 5-HT receptors, most notably the psychedelic alkaloid 5-methoxy-N,Ndimethyltryptamine (5-MeO-DMT) 30 and the antidepressant agomelatine 12, 13 , albeit with reduced potency. The docking model of agomelatine in the 5-HT 2C receptor shows a similar pose to the ergotamine core 31 , but has a perpendicular orientation to agomelatine in the MT 1 structure and involves completely different residues (Fig. 4) . This orthogonal binding mode and the low sequence conservation between melatonin and 5-HT receptors are testament to disparate evolution driven by their distinct cognate ligands. Their receptors are co-expressed in a number of tissues 32 , where promiscuous binding of endogenous molecules has to remain the exception. The two structurally similar ligands can be reliably discriminated by (i) structurally different binding pockets; in particular, the lack in melatonin receptors of an equivalent residue to negatively charged D 3.32 , which serves as primary anchor for all aminergic receptors; and (ii) the use of different physical ligand properties (restricting access of charged ligands to the MT 1 binding site through the membrane channel).
In conclusion, the binding site of melatonin in the MT 1 receptor is completely different from that of the related metabolite serotonin in 5-HT receptors, and the MT 1 receptor contains an unexpected channel that provides ligands lateral access to the receptor binding site from within the lipid bilayer. This channel represents a novel allosteric site that can be targeted by rational structure-based drug design. The atypical entry mechanism could impose constraints on ligand dimensions and physicochemical properties and can be exploited in the future development of synthetic melatonergic agents to address the need for safer sleeping aids without the potential for abuse, and for antidepressants that benefit from melatonin-5-HT polypharmacology by design.
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No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Design of thermostabilizing point mutations. Wild-type human MT 1 showed extremely low expression, yield, and stability for pursuing structural studies. To predict stabilizing point mutations, we searched the MT 1 reference sequence (UniProt 33 identifier P48039) against the database of non-redundant (nr) protein sequences using the blastp algorithm 34, 35 , excluding 'low quality' and exactly identical sequences. Standard parameters were used, and alignments were scored using the BLOSUM62 matrix. The 100 closest identified homologues were aligned using COBALT 36 , yielding the sequence conservation profile P MT1 for receptor species orthologues. Next, a conservation profile Q ClassA for all transmembrane residues of human class A GPCRs (that is, paralogous sequences) was generated using the structure-guided sequence alignment of GPCRdb 22, 37 . Corresponding residues in P MT1 and Q ClassA were mapped using the generic residue numbering of GPCRdb 37 for the sequence of human MT 1 , which is contained in both alignments. For each of these residues, the dissimilarity of the two conservation profiles was quantified using the Kullback-Leibler divergence 38 D KL (P||Q) with P(i) and Q(i) being the relative frequencies of each amino acid in profiles P MT1 and Q ClassA , respectively, for that particular residue. Residues were ranked from most to least diverging, and the top twenty most divergent residues were mutated and tested. Of all mutations identified, A Crystallization of MT 1 . The codon-optimized nucleotide sequence of human MT 1 was synthesized by GenScript and subcloned into a modified pFastBac1 baculovirus expression vector (Invitrogen) containing an N-terminal haemagglutinin (HA) signal sequence, Flag tag, 10× His tag, and PreScission protease (PSP) cleavage site. Site-directed mutagenesis was carried out using oligonucleotides (IDT) with internal mismatches and AccuPrime Pfx polymerase (Thermo Fisher Scientific) and verified by Sanger sequencing (Genewiz). After truncating 11 N-terminal (including both glycosylation sites of the receptor) and 25 C-terminal amino acids, we replaced intracellular receptor amino acid residues 219-227 with the 196-aminoacid catalytic domain of Pyrococcus abyssi glycogen synthase (PGS, UniProt Q9V2J8) 15 . Several beneficial point mutations were identified (see above), nine of which were used in the final crystallized construct (MT 1 -CC).
The resulting MT 1 -CC chimaera was expressed in Spodoptera frugiperda (Sf9, purchased from ATCC, CRL-1711, authenticated by supplier using morphology and growth characteristics, certified mycoplasma-free) insect cells using the Bac-to-bac baculovirus expression system (Invitrogen). Cells with a density of (2-3) × 10 6 cells ml −1 were infected with baculovirus at 27 °C at a multiplicity of infection of 5, harvested by centrifugation 48 h after infection and stored at −80 °C until use. The membrane fraction was isolated from 3 l of biomass using repeated Dounce homogenization and ultracentrifugation in hypotonic (twice, 10 mM HEPES pH 7.5, 10 mM MgCl 2 , 20 mM KCl) and hypertonic (three times, 10 mM HEPES pH 7.5, 10 mM MgCl 2 , 20 mM KCl, 1 M NaCl) buffer. After membrane isolation, the ligand (ramelteon, Apex Biosciences; agomelatine, Sigma-Aldrich; 2-phenylmelatonin, Tocris; or 2-iodomelatonin, Tocris) concentration was 100 µM in all buffers.
Washed membranes were incubated in hypotonic buffer in the presence of 2 mg ml −1 iodoacetamide (Sigma-Aldrich) for 45 min, and receptor was subsequently extracted from membranes in a volume of 200 ml by addition of 2× solubilization buffer (100 mM HEPES pH 7.5, 300 mM NaCl, 2% (wt/vol) n-dodecyl-β-d-maltopyranoside (DDM, Anatrace) and 0.4% (wt/vol) cholesterol hemisuccinate (CHS, Sigma-Aldrich)) for 3 h. After overnight incubation with 1 ml of Talon (immobilized metal affinity chromatography, IMAC) resin (Clontech) in the presence of 150 mM NaCl and 20 mM imidazole, the sample was washed on a gravity column (Bio-Rad) with 12 column volumes (cv) of wash buffer 1 (50 mM HEPES pH 7.5, 800 mM NaCl, 25 mM imidazole pH 7.5, 10 mM MgCl 2 , 10% (vol/vol) glycerol, 0.05%/0.01% (wt/vol) DDM/CHS) followed by 6 cv of wash buffer 2 (50 mM HEPES pH 7.5, 150 mM NaCl, 50 mM imidazole, 10% (vol/vol) glycerol, 0.025%/0.005% (wt/vol) DDM/CHS). The sample was eluted in 3.75 cv of elution buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 250 mM imidazole pH 7.5, 10% (vol/vol) glycerol, 0.025%/0.005% (wt/vol) DDM/CHS) after discarding the first 0.6 cv of elution flow-through, and subsequently concentrated to a volume of about 400 µl using an Amicon centrifugal filter with 100 kDa molecular weight cutoff (Millipore). The concentrated sample and 30 IU of His-tagged PSP (GenScript) were concomitantly passed over a PD MiniTrap G-25 desalting column (GE Healthcare) to remove imidazole and adjust detergent concentration to 0.05%/0.01% (wt/vol) DDM/CHS. After overnight incubation, cleaved tags and protease were removed by reverse IMAC, and the receptor was concentrated to ~20-30 mg ml −1 as above. The receptor was reconstituted into LCP by mixing two volumes of purified receptor with three volumes of molten monoolein/cholesterol (9:1 wt/wt) using coupled gas-tight 100-µl syringes (Hamilton) as previously described 44 . For initial crystallization trials, protein-laden LCP boli (40 nl) were dispensed and overlaid with 800 nl precipitant in 96-well glass sandwich plates (Marienfeld) using the NT8-LCP system (Formulatrix). Initial crystals of MT 1 bound to the highaffinity agonists ramelteon and 2-PMT were 30-50 µm in size in the maximum dimension and could not be optimized to diffract better than 5 Å at a microfocus synchrotron beamline (Extended Data Fig. 1a, b) . We then shifted our focus to obtaining small, high-density crystals grown in syringes 45 . To prepare samples for XFEL data collection, strings of 5 µl protein-laden LCP were injected into syringes containing 50 µl precipitant solution (60-100 mM potassium phosphate monobasic, 32-35% (vol/vol) PEG 400, 100 mM HEPES pH 7.0, 1 mM ligand, 2.5% (vol/vol) DMSO, 1.5% (vol/vol) propan-2-ol), and incubated for 3-10 days at 17 °C. After expulsion of excess precipitant, equivalent syringes were pooled together, and consolidated samples were reconstituted by addition of 7.9 monoacylglycerol (MAG) lipid 46 . Crystallographic data collection, structure solution and refinement. Data were collected at the CXI instrument of the Linac Coherent Light Source (LCLS) 47 at photon energies of 9.52 and 9.83 keV, pulse durations of 30 and 43 fs, pulse repetition rate of 120 Hz, approximately 10 11 photons per pulse (5-11% transmission), and beam size 1.5 × 1.5 µm 2 . MT 1 -CC micro-crystals (~5-10 µm maximum dimension, Extended Data Fig. 1c ) were delivered at room temperature in a vacuum chamber to the intersection with the XFEL beam using an LCP jet viscous medium injector 46 with a 50-µm nozzle at a flow rate of 0.3-0.36 µl min −1 , and diffraction images were collected using the CSPAD detector 48 . Crystal hits were identified using Cheetah 49 (more than 20 Bragg peaks of minimum 3 pixels in size with a signal-to-noise ratio better than 4 using an intensity threshold of 200 detector intensity units). Patterns were indexed, integrated, and merged with CrystFEL (v0.6.2) 50 , using MOSFLM 51 −1 above the conservative resolution estimates for each crystal were used (push-res option). The default values were used for all other options. On the basis of apparent metric symmetry, data were first processed in a cubic space group; however, no molecular replacement solution could be found. A tetragonal lattice was then considered with the length of the unique axis c very close to that of the other two axes. This led to an indexing ambiguity where each crystal could be indexed in three different ways related by a permutation of the axes (hkl → klh → lhk). The correct assignment from the three options must be made for each crystal. Although the ambigator program implemented in CrystFEL can only distinguish between two possible indexing assignments at a time 54 , in this case the three-fold ambiguity could be resolved by applying the algorithm iteratively at least twice using the same axis permutation operator hkl → klh, which generates all three indexing options cyclically.
The structure of MT 1 -CC-2-PMT was then solved by molecular replacement (MR) in space group P4 2 1 2 using the backbone of the helical bundle of the human OX 2 orexin receptor 15 (PDB ID: 4S0V) as a search model, followed by a separate search against the PGS coordinates from the same structure using Phaser 2.1 55 .
One copy of each molecule in the asymmetric unit was readily identified with TFZ scores (Z-score of the translation function) of 9.8 for both partial and final solution. The packing in our MT 1 crystals was found to be predominantly mediated by PGS, with the receptor crystallized as a monomer in the asymmetric unit, forming a layered structure with receptors from adjacent layers coordinated head to head (Extended Data Fig. 1f) .
All refinements were performed using Refmac5 56 and Buster v.2.10.2 57 followed by manual examination and rebuilding of the refined coordinates in the program Coot 58 using both 2mF o − DF c and mF o − DF c maps, as well as omit maps. Ligand restraints were generated using Prodrg 59 . The remaining three structures were solved by MR using the pruned protein coordinates of MT 1 -CC-2-PMT as a search model, and repeating the refinement procedure described above. The Ramachandran plot determined by MolProbity 60 indicates that with the exception of Y79 of the YPYP motif all residues are in favoured/allowed regions: 97.1/2.7% of residues (MT 1 -CC-ramelteon), 96/3.8% of residues in MT 1 -CC-2-PMT, 96.4/3.4% of residues in MT 1 -CC-2-iodomelatonin, 95.4/4.4% of residues in MT 1 -CCagomelatine. The final data collection and refinement statistics are shown in Extended Data Table 3 . Simulated annealing omit maps (mF o − DF c ) were calculated using Phenix 61 .
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Thermostability studies. To assess the stability of the solubilized receptor, 1-3 µg purified protein was incubated in a volume of 100 µl at 4 °C for 20 min in the presence of 1.5 µM 7-diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin (CPM, Sigma-Aldrich) 62 , added as a stock solution in DMSO (1% final concentration, vol/vol), 50 mM HEPES pH 7.5, 150 mM NaCl, 10% (vol/vol) glycerol, and 0.05%/0.01% (wt/vol) DDM/CHS. After incubation of the sample at room temperature for 5 min, thermal unfolding of the receptor was induced and monitored using a Rotor-Gene Q instrument (QIAGEN) between 25 °C and 95 °C (+2 °C min −1 ) at wavelengths of 365 nm (excitation) and 460 nm (emission), and gain settings of −2 to −1, and melting temperatures were extracted from the first derivative of the melting curve. Synthesis of bitopic compound. N-{2-[7-(2-{2-[8-(2-Acetylaminoethyl) naphthalen-2-yloxy]-ethoxy}-ethoxy)-naphthalen-1-yl]-ethyl}acetamide (compound 2, CTL 01-05-B-A05) was obtained in one step by condensation of the described 63 N-[2-(7-hydroxynaphth-1-yl)ethyl]acetamide (1) with bis(2-bromoethyl)ether in the presence of potassium carbonate in acetonitrile 64 . The synthesis scheme, experimental section, and NMR spectra are shown in Supplementary Figs. 7, 8 . Radioligand binding assays. Binding assays were performed using HEK293T cells (purchased from ATCC, CRL-11268, authenticated by supplier using morphology, growth characteristics and STR profiling, certified mycoplasma-free) transfected with wild-type or mutants of MT 1 . All binding assays were performed in standard binding buffer (50 mM Tris, 10 mM MgCl 2 , 0.1 mM EDTA, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) using [ For all assays, non-specific activity was defined as the addition of 5 µM 2-PMT. For determining the effect of NaCl on melatonin binding affinity, 147 mM NaCl was included in the binding buffer. Plates were harvested using vacuum filtration onto 0.3% polyethyleneimine pre-soaked 96-well Filtermat A (PerkinElmer) and washed three times with 250 µl per well of cold wash buffer (50 mM Tris, pH 7.4). Filters were dried and scintillation cocktail (Meltilex, PerkinElmer) was melted and allowed to cool to room temperature. Afterwards, filter plates were placed in cassettes and read using a Wallac TriLux Microbeta counter (PerkinElmer). Data were analysed either using 'One-site-homologous' (to yield K d ) or 'One-site-Fit K i ' (to yield K i ) using GraphPad Prism 7.0. MT 1 G i/o -mediated cAMP inhibition assay. MT 1 G i/o -mediated cAMP inhibition assays were performed in HEK293T cells (ATCC CRL-11268, mycoplasma-free) co-expressing the cAMP biosensor GloSensor-22F (Promega) and human MT 1 . Transfected cells were seeded (10-15,000 cells per 40 µl per well) into poly-llysine-coated white 384 clear-bottom tissue culture plates in DMEM containing 1% dialysed FBS. On the next day, ligands were diluted from 10 µM to 100 fmol in HBSS (Hank's balanced salt solution), 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4. Medium was removed on 384-well plates and 20 µl drug buffer (HBSS, 20 mM HEPES, pH 7.4) was added per well and allowed to equilibrate for at least 15 min at room temperature. To start the assay, cells were treated with 5 µl per well of 5× concentrated ligands in HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4 using a FLIPR (Molecular Devices). After 15 min, cAMP accumulation was initiated by addition of 10 µl per well of 0.3 µM isoproterenol (final concentration) in GloSensor reagent. Luminescence per well per second (LCPS) was read on a Wallac TriLux Microbeta counter (PerkinElmer). Data were normalized to maximum cAMP inhibition by melatonin (100%) and basal cAMP accumulation by isoproterenol (0%), and analysed using the sigmoidal dose-response function in GraphPad Prism 7.0. Transmembrane segment sequence analysis. To analyse amino acid frequencies and distributions in transmembrane segments, two data sets were constructed: one data set comprising experimentally determined, representative structures of membrane proteins (experimental-TM); and one data set comprising the subset of the human proteome with transmembrane regions predicted by a computational method (human-TM).
The experimental-TM data set was constructed as follows. A list of experimental polypeptide X-ray structures was retrieved from the OPM database 65 , which provides quaternary assemblies and membrane boundaries for all experimental membrane protein structures from the Protein Data Bank 66 . Because OPM also contains non-helical proteins (for example, β-barrel folds) that would skew our analysis, only entries containing at least one helical membrane-spanning element were retained. To this end, the secondary structure of each polypeptide chain was computed using DSSP 67 v3.0, and for each annotated TM segment that was determined to be at least 80% helical, leading and trailing non-helical residues were removed. After removing one more residue from either side so as to minimize contamination by flanking regions, segments longer than 17 amino acids were retained. Next, for duplicate polypeptide chains only those with the highest resolution were retained. The unique chains were clustered hierarchically using single linkage clustering as implemented in the treecluster routine of Biopython 68 . When extracting amino acid sequences, only residues with a residue numbering between 1 and 999 were retained to eliminate expression tags and soluble GPCR fusion partners. Distances were calculated from global sequence alignments for each pair of sequences, using the pairwise2 routine of Biopython with gap open and extension penalties of −10 and −0.5 and the BLOSUM62 substitution matrix 69 . Gaps at alignment ends were not penalized, and sequence identity (in %) was calculated over all experimentally observed residues and converted to distance as 1 − identity/100%. The 'tree' resulting from the clustering was cut and clades collapsed to clusters with representative polypeptide chains chosen from each cluster such that (i) cluster representatives had the minimum average distance to all other entries in the same cluster, and (ii) cluster representatives were at most 95% identical to each other. The cluster representatives then formed a balanced data set of 2,965 TM segments in 741 polypeptide chains and 546 PDB entries with reduced sequence bias.
To construct the human-TM data set, 20,245 reference sequences representing the human proteome were downloaded from UniProt 33 and submitted to the TMHMM Server v2.0 70 to computationally predict TM segments. This analysis identified 5,225 proteins with at least one TM segment of no less than 18 amino acids, 2,286 of which were single-pass proteins, and 18,959 such TM segments overall.
The observed amino acid frequencies in the TM segments of the two data sets were compared to their expected frequencies, which were calculated by shuffling the primary sequence of each protein in the data set, and counting the occurrence of a given amino acid in a fraction of the length of that randomized sequence that corresponds to the experimentally determined or computationally predicted TM content (see above). Statistics were accumulated per data set by shuffling each protein sequence 10,000 times, with the average count for a given amino acid approximating its expected value. Despite amino acid counts being discrete, they were found to be sufficiently well represented by a normal distribution, as manually inspected by quantile-quantile plots. Significance was estimated by comparing the observed count with the sample mean of the distribution of 10,000 randomized counts and integrating over the two more extreme tails of this distribution. Similarly, patterns of consecutive amino acids were analysed in both data sets following the outline of an earlier study 71 . Observed counts for patterns in TM segments were compared to expected counts given the distribution of individual amino acids in TM segments; that is, instead of randomizing the entire protein sequence as above, only amino acids within TM segments were shuffled, and instances of a given pattern were counted in this randomized set of (independent) TM segments. Statistics were accumulated and P values estimated as above.
We analysed the two data sets for the occurrence of the YPYP motif and, given the significantly lower abundance of proline residues in TM segments (observed fraction 0.51-0.66 of their expected number in human proteome and PDB, respectively, P < 0.0001), found this motif occurring in melatonin receptors to be statistically significant (P < 0.025), and not to exist in receptors other than the melatonin receptors. Cheminformatics. Ligand data sets for a given receptor, identified by its UniProt 33 accession, were retrieved from ChEMBL24 23 , and limited to data points with available binding ('B') data. Affinities were converted to pK i , and for ligands with multiple reported affinity values, pK i values were averaged. Substructure searches and matching were performed with rdkit (http://www.rdkit.org), and ligand protonation states estimated with OpenBabel 72 at pH 7.4. Channel diameter determination. Channel dimensions were obtained using the CAVER analyst v2.0 73 . After addition of hydrogens to the coordinates of the MT 1 -ramelteon crystal structure using PyMOL 74 , a tunnel starting point was placed manually close to the perceived channel entrance. Using default program parameters, channel dimensions were extracted and trimmed to the segment between the channel entrance and ligand centroid. The residue proximity matrix was calculated for pore-lining residues within 5 Å of the respective probe position, with distances calculated as minima to any residue atom including hydrogens. Molecular docking. MT 1 ligands obtained from the ChEMBL database 23 were docked into the ramelteon-bound crystal structure using energy-based docking in ICM-Pro v3.8-6 75 . Receptor structures were optimized using ICM docking protocols. Ligands selected for docking were converted from chemical structures to optimize their three-dimensional geometry and charges according to the MMFF force field 76 . Docking grid maps were generated using the receptor model, and ligands were docked using the biased probability Monte Carlo (BPMC) sampling and optimization method with a conformational sampling thoroughness of 50, starting with random initial ligand conformations. At least five independent runs were performed for the docking of the ligand set, and consistent dock poses were selected for further interaction analysis. The docking protocol did not use distance restraints or any other a priori derived information to guide ligandreceptor interactions. The same procedure was applied to dock agomelatine to the 5-HT 2C structure 31 (PDB ID: 6BQG). Molecular dynamics simulation. The experimental structure of MT 1 was preprocessed to assign protonation states and to model missing side chains using ICMFF energy-based optimization protocols available in the ICM-Pro molecular modelling package 75 (v3.8-6). The missing ICL3 coordinates were modelled using loop modelling and regularization protocols in ICM-Pro. The pre-processed structure was subjected to molecular dynamics simulation as previously described 77 , using input files generated by the CHARMM-GUI web server 78 . For initial membrane embedding, the MT 1 models were superimposed to the 5-HT 2B (PDB ID: 4NC3) receptor structure 79 retrieved from the OPM database 65 . The structure was simulated in a periodic box with dimensions (x, y, z) of 75.5 Å, 75.5 Å, 105.4 Å, containing lipids (129 copies of the POPC lipid), 10,284 water molecules, 27 sodium ions, and 41 chloride ions. Parameters for melatonin and 2-PMT were obtained using CGenFF 80 , available with the CHARMM-GUI server. After the initial energy minimization, the system was equilibrated for 10 ns, followed by production runs of up to 1 µs.
Membrane boundaries were derived as follows: for a set of 1,000 snapshots evenly spaced in time across the 1-µs trajectory, coordinates were superimposed to the crystal structure reference to eliminate receptor motion, the membrane being oriented along the x-y plane. Then, the positions of the carbonyl oxygen atoms of POPC molecules furthest from the lipid head groups were used to represent the boundaries of the hydrophobic slab. For each snapshot, this yielded a set of 129 oxygen atom coordinates, 64 (65) of which represent the upper (lower) leaf of the bilayer. Next, two planes were fit to these coordinates, representing the upper and lower membrane boundaries, respectively, using a least-squares method, minimizing the vertical (z-coordinate) distance from the points to the plane. The parameters of the resulting pair of planes were used to determine statistics over the course of the simulation, such as bilayer thickness and buriedness of the lateral ligand access channel below the extracellular membrane leaf, the position of which was defined as the mid-point between the smallest and largest z-coordinate of the side chains of channel-lining receptor residues Y187 5.38 and H195 5.46 , respectively. This channel coordinate was found to fluctuate very little over the course of the simulation (s.d. = 0.4 Å). The channel entrance was found to lie 6.5 to 10.9 Å below the upper boundary of the hydrophobic slab (values from quartiles of the distance distribution; mean 8.7 ± 3.4 Å s.d., median 8.8 Å), and the average thickness of the hydrophobic slab was 30.0 ± 1.7 Å. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
Data availability
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code Data collection XFEL data were collected at the CXI instrument at LCLS using in-house DAQ software.
